Inclusion Criteria:  The patient is at least 18 years old with no gender limitation; Patients with advanced malignant solid tumors confirmed by histopathology or cytology and failed to receive standard treatment or without standard treatment; Identification of at least one KRAS mutation: G12C, G12D or G12V; The subtype was identified as HLA-A11:01 or C08:02; Have at least one measurable lesion according to RECIST V1.1; ECOG PS score was 0-2 in the Eastern Oncology Group; Full organ and bone marrow function, as defined below: Sign written informed consent and be able to comply with the visits and related procedures specified in the program; Eligible fertile patients (male and female) must agree to use a reliable contraceptive method (hormonal or barrier methods or abstinence) during the study period;  Exclusion Criteria:  A history of severe allergy to biological products; Those in pregnancy or lactation; The expected survival time is less than 3 months; Those who have undergone major surgery within 4 weeks prior to signing the informed consent, or who plan to undergo major surgery during the study period; Received chemotherapy, biotherapy, endocrine therapy, immunotherapy and other anti-tumor drugs within 2 weeks before the first administration; Participating in other clinical studies; Patients with central nervous system metastasis or a history of central nervous system metastasis; Adverse effects of previous antitumor therapy have not recovered to NCI CTCAE V5.0 rating ≤1 (except hair loss); Serious cardiovascular and cerebrovascular diseases, hypertension that is still poorly controlled after standard treatment (systolic blood pressure > 150mmHg, diastolic blood pressure > 90mmHg); Patients with active ulcers and gastrointestinal bleeding; Patients with uncontrollable pleural effusion, abdominal effusion and pericardial effusion; Active infection requiring treatment; HIV, HCV, syphilis, CMV, EBV infected patients; Patients with active HBV replication; A history of interstitial lung disease; The patient has an autoimmune disease or is in an immunosuppressed state; Current systemic steroid use (except recent or current inhaled steroid use); Other conditions that the investigator assessed as ineligible for inclusion.